Clindamycin
Class
Lincosamide
Dose
600mg IV q8h (Nec Fasc)
450mg PO q8h
Mechanism
Bacteriostatic
MoA
50S inhibitor
Inhibits protein synthesis
Time v Concentration
TIME > MIC
Post dose effect
Short
Spectrum
Covers
Doesn't Cover
G +ves
Anaerobes
No G-ve cover
Enterococci
1-% MSSA resistance
Indications
Skin/soft tissue infections – ANTITOXIN EFFECT for toxic shock/nec fasc
Lung abscess
Sinusitis
Pelvic infections
Penicillin allergy
PK
A
90% PBA
D
Wide distribution, 90%PPB
M
Metabolised, partially inactive metabolites
E
10% unchanged in urine
Rest as inactive metabolites
Prolonged DoA with renal & hepatic failure
A/E
Highest rate of C diff among all a/b (5-10%)
Skin – rash/allergies
Resistance
5-10% MSSA
Monitoring
LFT
Bowel/stool monitoring